• Covid-19 All the details of the vaccination of children

The Pfizer


is much less effective in children between the ages of 5 and 11 when it comes to preventing the spread of


than in older children and adults, although it does work when it comes to preventing the most serious effects of the virus.

The conclusion comes from a study led by six researchers from

the New York Department of Health

that opens the door to modifying the dose in this population group, a third with respect to those over 12 years of age.

The report, carried out between December 13 and January 20, reflects how the effectiveness of the vaccine against the spread of the coronavirus went from 66% to 51% in young people between 12 and 17 years old in that period of time, a percentage which

decreased to 12%

in the case of children aged 5 to 11 years.

It is a step backwards for both the pharmaceutical company and parents in the United States, since it is the only vaccine available for that age at the national level.

The results make it clear that

protection against infection is almost nil

even one month after receiving the full regimen.

Eli Rosenberg

, deputy director of the New York State Department of Health and the person leading the study, said she was disappointed but not entirely surprised "since it's a vaccine developed for a previous variant," not for omicron, the dominant one during the period in which the tests were carried out.

The key seems to lie in the dose, from the 30 micrograms assigned for children over 12 years of age to the

10 micrograms

that it was decided to give to those between 5 and 12 years of age.

The possibility of collecting more information and changing the approach remains open despite the pronounced decrease in positives at the national level and the lesser effect of the coronavirus on children.

On Monday the numbers spoke of an average of 65,000 positives nationwide -62% more than two weeks ago-, 1,876 deaths per day on average, and close to breaking the barrier of 50,000 hospitalized by Covid throughout the country, far from 156,000 registered at the beginning of the year.

The data in the report is

in line with that of clinical trials conducted in children 2 to 4 years

of age.

They were disappointing with a dose even lower than the population group between 5 and 12 years.

They also coincide with the announcement of the Centers for Disease Control and Prevention (CDC) on Friday that eliminates the obligation to wear masks in schools in areas with low risk of contagion.

The problem with the possible increase in dosage is the side effects that could occur, including constant fevers.

The other route would be a third booster dose, currently being tested by Pfizer, an option that has been shown to be effective in adults.

Conforms to The Trust Project criteria

Know more

  • Coronavirus

  • United States

  • CDC

  • covid 19

SaludPfizer requests approval for its pediatric vaccine against coronavirus in children under 5 years of age

Crisis Emmanuel Macron reaches out to Vladimir Putin in Moscow to "start a de-escalation"

HealthThe EMA approves the Moderna vaccine for children between 6 and 11 years old

See links of interest

  • Ukraine

  • Foster children Ukraine

  • Last News

  • Topics

  • Work calendar 2022

  • Time change

  • best colleges

  • Atalanta - Sampdoria

  • Granada CF - Cadiz

  • Malaga - FC Cartagena